$-1.26 EPS Expected for Mirati Therapeutics, Inc. (MRTX)

Mirati Therapeutics, Inc. (NASDAQ:MRTX) Logo
Investors sentiment decreased to 1.73 in Q2 2019. Its down 0.65, from 2.38 in 2019Q1. It fall, as 23 investors sold Mirati Therapeutics, Inc. shares while 33 reduced holdings. 47 funds opened positions while 50 raised stakes. 37.63 million shares or 8.46% more from 34.70 million shares in 2019Q1 were reported.
Moreover, Tiverton Asset Management Limited Liability Com has 0.01% invested in Mirati Therapeutics, Inc. (NASDAQ:MRTX) for 1,550 shares. Fmr Ltd Llc has 2.93M shares. Trexquant Lp owns 3,660 shares. State Street reported 1.14M shares or 0.01% of all its holdings. Eventide Asset Limited Liability reported 243,000 shares or 0.76% of all its holdings. Sei Invests reported 12,195 shares or 0% of all its holdings. Tekla Cap Mngmt holds 13,590 shares or 0.06% of its portfolio. Moreover, New York State Common Retirement Fund has 0% invested in Mirati Therapeutics, Inc. (NASDAQ:MRTX). First Mercantile Tru Company owns 868 shares. Wells Fargo And Mn has 267,983 shares for 0.01% of their portfolio. Alliancebernstein Ltd Partnership holds 58,123 shares. Credit Suisse Ag stated it has 236,460 shares or 0.02% of all its holdings. Voya Investment Mngmt holds 9,919 shares or 0% of its portfolio. Stifel Fin Corp owns 3,628 shares for 0% of their portfolio. Deutsche Commercial Bank Ag holds 0.02% or 322,207 shares.

Since July 17, 2019, it had 0 insider buys, and 2 sales for $77.64 million activity. 725,008 shares valued at $71.27 million were sold by Boxer Capital – LLC on Wednesday, July 17.

Analysts expect Mirati Therapeutics, Inc. (NASDAQ:MRTX) to report $-1.26 EPS on November, 5.They anticipate $0.41 EPS change or 48.24 % from last quarter’s $-0.85 EPS. After having $-1.26 EPS previously, Mirati Therapeutics, Inc.’s analysts see 0.00 % EPS growth. The stock increased 0.57% or $0.42 during the last trading session, reaching $73.55. About 719,509 shares traded or 38.47% up from the average. Mirati Therapeutics, Inc. (NASDAQ:MRTX) has risen 68.74% since October 7, 2018 and is uptrending. It has outperformed by 68.74% the S&P500.

Mirati Therapeutics, Inc. (NASDAQ:MRTX) Ratings Coverage

Among 3 analysts covering Mirati Therapeutics (NASDAQ:MRTX), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. Mirati Therapeutics has $10500 highest and $6000 lowest target. $84.75’s average target is 15.23% above currents $73.55 stock price. Mirati Therapeutics had 12 analyst reports since April 17, 2019 according to SRatingsIntel. Cantor Fitzgerald maintained Mirati Therapeutics, Inc. (NASDAQ:MRTX) on Monday, September 9 with “Neutral” rating. The stock of Mirati Therapeutics, Inc. (NASDAQ:MRTX) has “Neutral” rating given on Wednesday, September 11 by B. Riley & Co. The rating was upgraded by Jefferies on Monday, September 9 to “Buy”.

Mirati Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The company has market cap of $2.80 billion. The company's clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors. It currently has negative earnings. The Company’s clinical stage product candidates also comprise sitravatinib, an orally-bioavailable, potent, small molecule spectrum-selective kinase inhibitor, which is in Phase II clinical trials for the treatment of solid tumors, such as NSCLC and metastatic Renal Cell Carcinoma, as well as in Phase Ib clinical trials to treat NSCLC patients with RET, CHR4q12, CBL, and AXL genetic alterations; and mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor, which is in Phase Ib/II clinical trials in combination with durvalumab for the treatment of patients with NSCLC.

More notable recent Mirati Therapeutics, Inc. (NASDAQ:MRTX) news were published by: Prnewswire.com which released: “Mirati Therapeutics Announces Proposed Public Offering of Common Stock – PRNewswire” on June 24, 2019, also Fool.com with their article: “How Amazon Is Shaking Up Telemedicine, Plus 1 Winner and 1 Loser Exiting ESMO – The Motley Fool” published on October 04, 2019, Zacks.com published: “Options Traders Expect Huge Moves in Mirati Therapeutics (MRTX) Stock – Zacks.com” on May 14, 2019. More interesting news about Mirati Therapeutics, Inc. (NASDAQ:MRTX) were released by: Benzinga.com and their article: “The Daily Biotech Pulse: Immunomedics CEO Departs, Ultragenyx Offering, Karyopharm Awaits FDA Panel Vote – Benzinga” published on February 26, 2019 as well as Benzinga.com‘s news article titled: “44 Stocks Moving In Monday’s Mid-Day Session – Benzinga” with publication date: September 09, 2019.

Mirati Therapeutics, Inc. (NASDAQ:MRTX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.